Beta-Blockers for Primary Prevention of Anthracycline-Induced Cardiac Toxicity: An Updated Meta-Analysis of Randomized Clinical Trials.
Armin AttarArman Karimi BehnaghMehrasa HosseiniFoad AmanollahiParia ShafiekhaniAli KabirPublished in: Cardiovascular therapeutics (2022)
Treatment with beta-blockers prevents dilatation of the left ventricle, development of diastolic dysfunction, and reduction of LVEF. However, these hemodynamic effects do not translate into a significant reduction in CTRCD incidence and prevention of hospitalization for heart failure or cardiac death.
Keyphrases
- left ventricular
- heart failure
- angiotensin converting enzyme
- oxidative stress
- mitral valve
- cardiac resynchronization therapy
- diabetic rats
- blood pressure
- high glucose
- pulmonary hypertension
- risk factors
- clinical trial
- atrial fibrillation
- angiotensin ii
- endothelial cells
- combination therapy
- congenital heart disease
- pulmonary arterial hypertension